X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: Billing code basics for biologics in Part B

By Allyson Funk  |    March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would...   Read More

FDA issues draft biosimilars labeling guidance

By Andrew Powaleny  |    April 12, 2016
Labeling is an important aspect of the U.S. Food and Drug Administration (FDA) prescription drug approval process. FDA-approved prescription drug labeling is the most authoritative mechanism for...   Read More

The biopharmaceutical industry’s commitment to quality

By Camille Jackson  |    February 11, 2016
America’s innovative biopharmaceutical companies are leaders in innovation and quality—not just in research and development, but also in manufacturing technology. PhRMA’s member companies...   Read More

PhRMA and BIO Citizen Petition to FDA calls for biosimilar labeling guidance

By Jeff Francer  |    January 21, 2016
Biosimilars will continue to become more widely available to patients in 2016 and beyond.  PhRMA supports science-based regulation of biosimilars by the Food and Drug Administration (FDA)....   Read More

PhRMA launches biologics and biosimilars online resources

By Andrew Powaleny  |    December 17, 2015
Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other...   Read More

Medicare Monday: Part B and biosimilars, part 2

By Kelsey Lang  |    November 30, 2015
Earlier this month, Medicare Monday covered the Center for Medicare & Medicaid Services (CMS) final rule on reimbursement for biosimilars and the implications of using a single billing code to...   Read More

Medicare Monday: Medicare Part B and biosimilars

By Andrew Powaleny  |    November 16, 2015
With the first U.S. biosimilar approved in March of 2015, the pathway created by the Biologics Price Competition and Innovation Act to bring biosimilars to market for U.S. patients has become a...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates